Novartis To Establish Texas Radioligand Therapy Manufacturing Site, Expands Network With New Denton Facility

Novartis AG announced plans to build a new 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas. The purpose-built site will be Novartis’ fifth RLT manufacturing location in the United States and its first in Texas, and will form part of the company’s broader $23 billion investment strategy in the US. Construction is expected to begin this year, with operations slated to commence in 2028.

The Denton facility is projected to create new roles across bioengineering, advanced manufacturing, quality, and operations, contributing to economic development in the local community and surrounding region. The expansion reflects Novartis’ continued focus on strengthening domestic manufacturing capacity for innovative cancer therapies.

“RLT has the potential to revolutionize cancer care,” said Vas Narasimhan, CEO of Novartis. “The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”

Once operational, the Texas plant will integrate into Novartis’ existing US RLT manufacturing network, which includes facilities in New Jersey, Indiana, and California, along with a recently announced site in Florida. This coast-to-coast infrastructure is designed to ensure timely delivery of custom-made, time-sensitive RLT doses, with the network historically enabling more than 99% of treatments to be administered as scheduled.

“Texas is a leading biotech hub and home to groundbreaking advancements in medicine,” said Governor Greg Abbott. “This significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.”

Radioligand therapy represents a key pillar of Novartis’ oncology strategy, combining targeted radiation with molecular precision to treat advanced cancers. The company maintains one of the industry’s most advanced RLT pipelines, with ongoing clinical trials across multiple tumor types, including prostate, breast, colon, lung, brain, and pancreatic cancers, supported by a global manufacturing and supply chain network.